- Home
- PRLD vs VTGN Comparison
PRLD vs VTGN Comparison
Compare PRLD & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- VTGN
- Stock Information
- Founded
- PRLD 2016
- VTGN 1998
- Country
- PRLD United States
- VTGN United States
- Employees
- PRLD N/A
- VTGN N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- PRLD Health Care
- VTGN Health Care
- Exchange
- PRLD Nasdaq
- VTGN Nasdaq
- Market Cap
- PRLD 73.7M
- VTGN 82.7M
- IPO Year
- PRLD 2020
- VTGN N/A
- Fundamental
- Price
- PRLD $0.68
- VTGN $2.35
- Analyst Decision
- PRLD Strong Buy
- VTGN
- Analyst Count
- PRLD 2
- VTGN 0
- Target Price
- PRLD $4.50
- VTGN N/A
- AVG Volume (30 Days)
- PRLD 272.4K
- VTGN 123.6K
- Earning Date
- PRLD 05-06-2025
- VTGN 02-13-2025
- Dividend Yield
- PRLD N/A
- VTGN N/A
- EPS Growth
- PRLD N/A
- VTGN N/A
- EPS
- PRLD N/A
- VTGN N/A
- Revenue
- PRLD $7,000,000.00
- VTGN $698,000.00
- Revenue This Year
- PRLD N/A
- VTGN N/A
- Revenue Next Year
- PRLD N/A
- VTGN N/A
- P/E Ratio
- PRLD N/A
- VTGN N/A
- Revenue Growth
- PRLD N/A
- VTGN N/A
- 52 Week Low
- PRLD $0.63
- VTGN $2.15
- 52 Week High
- PRLD $6.80
- VTGN $5.41
- Technical
- Relative Strength Index (RSI)
- PRLD 41.40
- VTGN 37.32
- Support Level
- PRLD $0.71
- VTGN $2.58
- Resistance Level
- PRLD $0.76
- VTGN $2.69
- Average True Range (ATR)
- PRLD 0.07
- VTGN 0.16
- MACD
- PRLD 0.01
- VTGN -0.04
- Stochastic Oscillator
- PRLD 18.75
- VTGN 24.69
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.